AI & ChatGPT searches , social queries for MMAE

What is the meaning of MMAE. Phrases containing MMAE

See meanings and uses of MMAE!

AI & ChatGPT quick fun facts and cheerful jokes MMAE

MMAE

AI search for Acronyms & meanings containing MMAE

MMAE

Wiki AI search on online names & meanings containing MMAE

MMAE

Monomethyl auristatin E

Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked

Seagen

protease-cleavable linker to MMAE. This ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization

Brentuximab vedotin

to three to five units of the antimitotic agent monomethyl auristatin E (MMAE, reflected by the 'vedotin' in the drug's name). The peptide-based linker

Disitamab vedotin

conjugated to MMAE. The mechanism of action involves binding to HER2-positive tumor cells, followed by internalization and intracellular release of MMAE, which

Tisotumab vedotin

monoclonal antibody against tissue factor, and monomethyl auristatin E (MMAE), a potent inhibitor of cell division. It is administered by infusion into

Sigvotatug vedotin

monomethyl auristatin E (MMAE), and a protease-cleavable maleimidocaproyl-valine-citrulline (mc-vc) linker that covalently attaches MMAE to the antibody. Integrin

Antibody–drug conjugate

monomethyl auristatin E or MMAE, a synthetic antineoplastic agent, to human-specific CD30-positive malignant cells. MMAE inhibits cell division by blocking

Enfortumab vedotin

to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. The most common side effects include fatigue, peripheral

Glembatumumab vedotin

Glembatumumab vedotin (also known as CDX-011 and CR011-vcMMAE) is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein

Hodgkin lymphoma

brentuximab vedotin, a CD30 antibody conjugated with a cytotoxic component MMAE, and the checkpoint inhibitors, nivolumab and pembrolizumab. Adding nivolumab